JZYY(SH:600750) Xin Lang Cai Jing·2025-12-15 13:33Core Viewpoint - China Resources Pharmaceutical (华润医药) has acquired a controlling stake in Jiangzhong Pharmaceutical (江中药业), changing its actual controller from Jiangxi State-owned Assets Supervision and Administration Commission to China Resources Limited [2][5]. Group 1: Acquisition and Control Changes - In May 2018, China Resources Pharmaceutical signed a strategic restructuring agreement with Jiangxi State-owned Assets Supervision and Administration Commission [2][5]. - In February 2019, China Resources Pharmaceutical's wholly-owned subsidiary invested approximately 4.2 billion yuan to acquire 51% of Jiangzhong Group, thus becoming its controlling shareholder [2][5]. - Jiangzhong Pharmaceutical's actual controller changed from Jiangxi State-owned Assets Supervision and Administration Commission to China Resources Limited following the acquisition [2][5]. Group 2: Management Changes - Jiangzhong Pharmaceutical announced the resignation of three board members due to work adjustments, effective immediately for one and pending for the others until a new board is elected [2][5]. - New board candidates have been nominated by the controlling shareholder, including experienced professionals from various sectors [6]. Group 3: Business Overview - Jiangzhong Pharmaceutical's main business segments include over-the-counter drugs, prescription drugs, and health consumer products [6]. - The flagship product, Jianwei Shoushi Pian (健胃消食片), has been a top seller since its launch in 1994, achieving 169 million boxes sold last year [6]. - The revenue from the over-the-counter drug segment decreased by 10.14% year-on-year in the first half of this year, which is higher than the overall revenue decline of the company [6].